{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:09:06Z","timestamp":1793304546015,"version":"4.5.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metab Brain Dis"],"DOI":"10.1007\/s11011-025-01697-5","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T09:25:50Z","timestamp":1756459550000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Targeting glucose transporters in parkinson\u2019s disease: a novel metabolic approach for disease modification"],"prefix":"10.1007","volume":"40","author":[{"given":"Gursimran","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shazia","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2450-2975","authenticated-orcid":false,"given":"Khadga Raj","family":"Aran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"1697_CR1","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s10545-013-9608-0","volume":"36","author":"NJ Abbott","year":"2013","unstructured":"Abbott NJ (2013) Blood\u2013brain barrier structure and function, and the challenges for CNS drug delivery. J Inherit Metab Dis 36:437\u2013449. https:\/\/doi.org\/10.1007\/s10545-013-9608-0","journal-title":"J Inherit Metab Dis"},{"issue":"22","key":"1697_CR2","doi-asserted-by":"publisher","first-page":"12583","DOI":"10.1021\/acsomega.0c01592","volume":"5","author":"J Ahlawat","year":"2020","unstructured":"Ahlawat J, Guillama Barroso G, Masoudi Asil S et al (2020) Nanocarriers as potential drug delivery candidates for overcoming the blood\u2013brain barrier: challenges and possibilities. ACS Omega 5(22):12583\u201312595. https:\/\/doi.org\/10.1021\/acsomega.0c01592","journal-title":"ACS Omega"},{"key":"1697_CR3","doi-asserted-by":"publisher","first-page":"3825","DOI":"10.1007\/s12035-016-9906-2","volume":"54","author":"A Anandhan","year":"2017","unstructured":"Anandhan A, Lei S, Levytskyy R, Pappa A, Panayiotidis MI, Cerny RL, Khalimonchuk O, Powers R, Franco R (2017) Glucose metabolism and AMPK signaling regulate dopaminergic cell death induced by gene (\u03b1-synuclein)-environment (paraquat) interactions. Mol Neurobiol 54:3825\u20133842","journal-title":"Mol Neurobiol"},{"issue":"4\u20136","key":"1697_CR4","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1089\/ars.2022.0016","volume":"39","author":"N Apostolova","year":"2023","unstructured":"Apostolova N, Vezza T, Muntane J, Rocha M, V\u00edctor VM (2023) Mitochondrial dysfunction and mitophagy in type 2 diabetes: pathophysiology and therapeutic targets. Antioxid Redox Signal 39(4\u20136):278\u2013320. https:\/\/doi.org\/10.1089\/ars.2022.0016","journal-title":"Antioxid Redox Signal"},{"key":"1697_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.102838","author":"PK Arnold","year":"2023","unstructured":"Arnold PK, Finley LWS (2023) Regulation and function of the mammalian tricarboxylic acid cycle. J Biol Chem. https:\/\/doi.org\/10.1016\/j.jbc.2022.102838","journal-title":"J Biol Chem"},{"key":"1697_CR6","doi-asserted-by":"publisher","first-page":"825816","DOI":"10.3389\/fphys.2021.825816","volume":"12","author":"E Beard","year":"2022","unstructured":"Beard E, Lengacher S, Dias S, Magistretti PJ, Finsterwald C (2022) Astrocytes as key regulators of brain energy metabolism: new therapeutic perspectives. Front Physiol 12:825816. https:\/\/doi.org\/10.3389\/fphys.2021.825816","journal-title":"Front Physiol"},{"issue":"15","key":"1697_CR7","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1212\/WNL.0000000000000328","volume":"82","author":"EE Benarroch","year":"2014","unstructured":"Benarroch EE (2014) Brain glucose transporters: implications for neurologic disease. Neurology 82(15):1374\u20131379. https:\/\/doi.org\/10.1212\/WNL.0000000000000328","journal-title":"Neurology"},{"key":"1697_CR8","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/j.expneurol.2004.08.021","volume":"191","author":"R Betarbet","year":"2005","unstructured":"Betarbet R, Sherer TB, Greenamyre JT (2005) Ubiquitin\u2013proteasome system and Parkinson\u2019s diseases. Exp Neurol 191:S17\u2013S27. https:\/\/doi.org\/10.1016\/j.expneurol.2004.08.021","journal-title":"Exp Neurol"},{"issue":"3","key":"1697_CR9","doi-asserted-by":"publisher","first-page":"174","DOI":"10.2174\/1871527319666200518102130","volume":"19","author":"SK Bhattamisra","year":"2020","unstructured":"Bhattamisra SK, Shin LY, Saad HIBM, Rao V, Candasamy M, Pandey M, Choudhury H (2020) Interlink between insulin resistance and neurodegeneration with an update on current therapeutic approaches. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders) 19(3):174\u2013183. https:\/\/doi.org\/10.2174\/1871527319666200518102130","journal-title":"CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders)"},{"key":"1697_CR10","doi-asserted-by":"publisher","first-page":"873301","DOI":"10.3389\/fendo.2022.873301","volume":"13","author":"E Bl\u00e1zquez","year":"2022","unstructured":"Bl\u00e1zquez E, Hurtado-Carneiro V, LeBaut-Ayuso Y, Vel\u00e1zquez E, Garc\u00eda-Garc\u00eda L, G\u00f3mez-Oliver F, Ruiz-Albusac JM, \u00c1vila J, Pozo M (2022a) \u00c1. Significance of brain glucose hypometabolism, altered insulin signal transduction, and insulin resistance in several neurological diseases. Front Endocrinol 13:873301. https:\/\/doi.org\/10.3389\/fendo.2022.873301","journal-title":"Front Endocrinol"},{"key":"1697_CR11","doi-asserted-by":"publisher","unstructured":"Bl\u00e1zquez Fern\u00e1ndez E, Carneiro H, Le Baut Ayuso V, Vel\u00e1zquez S\u00e1nchez Y, Garc\u00eda Garc\u00eda E, G\u00f3mez JL, Oliver F, Albusac R, \u00c1vila JM et al (2022) Significance of Brain Glucose Hypometabolism, Altered Insulin Signal Transduction, and Insulin Resistance in Several Neurological Diseases. https:\/\/doi.org\/10.3389\/fendo.2022.873301","DOI":"10.3389\/fendo.2022.873301"},{"issue":"5","key":"1697_CR12","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1210\/er.2003-0026","volume":"25","author":"C Bouche","year":"2004","unstructured":"Bouche C, Serdy S, Kahn CR, Goldfine AB (2004) The cellular fate of glucose and its relevance in type 2 diabetes. Endocr Rev 25(5):807\u2013830. https:\/\/doi.org\/10.1210\/er.2003-0026","journal-title":"Endocr Rev"},{"issue":"11","key":"1697_CR13","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1002\/mds.27128","volume":"32","author":"B Brakedal","year":"2017","unstructured":"Brakedal B, Fl\u00f8nes I, Reiter SF, Torkildsen \u00d8, D\u00f6lle C, Assmus J, Haugarvoll K, Tzoulis C (2017) Glitazone use is associated with reduced risk of Parkinson\u2019s disease. Mov Disord 32(11):1594\u20131599","journal-title":"Mov Disord"},{"issue":"7","key":"1697_CR14","doi-asserted-by":"publisher","first-page":"6085","DOI":"10.3390\/ijms24076085","volume":"24","author":"R Carb\u00f3","year":"2023","unstructured":"Carb\u00f3 R, Rodr\u00edguez E (2023) Relevance of sugar transport across the cell membrane. Int J Mol Sci 24(7):6085. https:\/\/doi.org\/10.3390\/ijms24076085","journal-title":"Int J Mol Sci"},{"key":"1697_CR15","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/978-1-62703-251-3_17","volume":"964","author":"AR Carta","year":"2013","unstructured":"Carta AR, Carboni E, Spiga S (2013) The MPTP\/probenecid model of progressive Parkinson\u2019s disease. Dopamine: Methods Protocols 964:295\u2013308. https:\/\/doi.org\/10.1007\/978-1-62703-251-3_17","journal-title":"Dopamine: Methods Protocols"},{"key":"1697_CR16","doi-asserted-by":"crossref","unstructured":"Carta AR, Greig NH, Borlongan CV (2022) Drug repurposing in neurodegenerative and neuropsychiatric disorders. Frontiers Media SA","DOI":"10.3389\/978-2-88974-168-7"},{"issue":"1","key":"1697_CR17","doi-asserted-by":"publisher","first-page":"10722","DOI":"10.1038\/s41598-018-28449-z","volume":"8","author":"S Chen","year":"2018","unstructured":"Chen S, Yu S-J, Li Y, Lecca D, Glotfelty E, Kim HK, Choi H-I, Hoffer BJ, Greig NH, Kim DS (2018) Post-treatment with PT302, a long-acting exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-hydroxydopamine rat model of parkinson\u2019s disease. Sci Rep 8(1):10722","journal-title":"Sci Rep"},{"issue":"1","key":"1697_CR18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40035-025-00467-8","volume":"14","author":"L Chen","year":"2025","unstructured":"Chen L, Wang C, Qin L, Zhang H (2025) Parkinson\u2019s disease and glucose metabolism impairment. Transl Neurodegener 14(1):10. https:\/\/doi.org\/10.1186\/s40035-025-00467-8","journal-title":"Transl Neurodegener"},{"issue":"1","key":"1697_CR19","doi-asserted-by":"publisher","first-page":"646354","DOI":"10.1155\/2012\/646354","volume":"2012","author":"H Cui","year":"2012","unstructured":"Cui H, Kong Y, Zhang H (2012) Oxidative stress, mitochondrial dysfunction, and aging. J Signal Transduct 2012(1):646354. https:\/\/doi.org\/10.1155\/2012\/646354","journal-title":"J Signal Transduct"},{"key":"1697_CR20","doi-asserted-by":"publisher","first-page":"110672","DOI":"10.1016\/j.brainresbull.2023.110672","volume":"199","author":"C Dai","year":"2023","unstructured":"Dai C, Tan C, Zhao L, Liang Y, Liu G, Liu H, Zhong Y, Liu Z, Mo L, Liu X (2023) Glucose metabolism impairment in Parkinson\u2019s disease. Brain Res Bull 199:110672. https:\/\/doi.org\/10.1016\/j.brainresbull.2023.110672","journal-title":"Brain Res Bull"},{"issue":"7","key":"1697_CR21","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.3390\/genes12071006","volume":"12","author":"JO Day","year":"2021","unstructured":"Day JO, Mullin S (2021) The genetics of parkinson\u2019s disease and implications for clinical practice. Genes 12(7):1006. https:\/\/doi.org\/10.3390\/genes12071006","journal-title":"Genes"},{"issue":"1","key":"1697_CR22","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1152\/physrev.00062.2017","volume":"99","author":"GA Dienel","year":"2019","unstructured":"Dienel GA (2019) Brain glucose metabolism: integration of energetics with function. Physiol Rev 99(1):949\u20131045. https:\/\/doi.org\/10.1152\/physrev.00062.2017","journal-title":"Physiol Rev"},{"issue":"21","key":"1697_CR23","doi-asserted-by":"publisher","first-page":"13043","DOI":"10.3390\/ijms232113043","volume":"23","author":"LP Dolgacheva","year":"2022","unstructured":"Dolgacheva LP, Zinchenko VP, Goncharov NV (2022) Molecular and cellular interactions in pathogenesis of sporadic Parkinson disease. Int J Mol Sci 23(21):13043. https:\/\/doi.org\/10.3390\/ijms232113043","journal-title":"Int J Mol Sci"},{"key":"1697_CR24","doi-asserted-by":"publisher","first-page":"108277","DOI":"10.1016\/j.pharmthera.2022.108277Getrightsandcontent","volume":"239","author":"F Ferrari","year":"2022","unstructured":"Ferrari F, Moretti A, Villa RF (2022) Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives. Pharmacol Ther 239:108277. https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108277Getrightsandcontent","journal-title":"Pharmacol Ther"},{"key":"1697_CR25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jalz.2013.12.005","volume":"10","author":"T Foltynie","year":"2014","unstructured":"Foltynie T, Aviles-Olmos I (2014) Exenatide as a potential treatment for patients with Parkinson\u2019s disease: first steps into the clinic. Alzheimers Dement 10:38\u201346. https:\/\/doi.org\/10.1016\/j.jalz.2013.12.005","journal-title":"Alzheimers Dement"},{"key":"1697_CR26","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.3389\/fnins.2018.01035","volume":"12","author":"C-A Gon\u00e7alves","year":"2019","unstructured":"Gon\u00e7alves C-A, Rodrigues L, Bobermin LD, Zanotto C, Vizuete A, Quincozes-Santos A, Souza DO, Leite MC (2019) Glycolysis-derived compounds from astrocytes that modulate synaptic communication. Front Neurosci 12:1035. https:\/\/doi.org\/10.3389\/fnins.2018.01035","journal-title":"Front Neurosci"},{"issue":"11","key":"1697_CR27","doi-asserted-by":"publisher","first-page":"5887","DOI":"10.3390\/ijms22115887","volume":"22","author":"R Han","year":"2021","unstructured":"Han R, Liang J, Zhou B (2021) Glucose metabolic dysfunction in neurodegenerative diseases\u2014new mechanistic insights and the potential of hypoxia as a prospective therapy targeting metabolic reprogramming. Int J Mol Sci 22(11):5887. https:\/\/doi.org\/10.3390\/ijms22115887","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1697_CR28","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12929-024-01090-x","volume":"31","author":"C-T Hong","year":"2024","unstructured":"Hong C-T, Chen J-H, Hu C-J (2024) Role of glucagon-like peptide-1 receptor agonists in Alzheimer\u2019s disease and Parkinson\u2019s disease. J Biomed Sci 31(1):102. https:\/\/doi.org\/10.1186\/s12929-024-01090-x","journal-title":"J Biomed Sci"},{"issue":"15","key":"1697_CR29","doi-asserted-by":"publisher","first-page":"8698","DOI":"10.3390\/ijms23158698","volume":"23","author":"A Ismail","year":"2022","unstructured":"Ismail A, Tanasova M (2022) Importance of GLUT transporters in disease diagnosis and treatment. Int J Mol Sci 23(15):8698","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1697_CR30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/jnc.13736","volume":"139","author":"J Jalewa","year":"2016","unstructured":"Jalewa J, Sharma MK, H\u00f6lscher C (2016) Novel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH-SY 5Y cells. J Neurochem 139(1):55\u201367. https:\/\/doi.org\/10.1111\/jnc.13736","journal-title":"J Neurochem"},{"key":"1697_CR31","unstructured":"Joharatnam-Hogan N, Carter TJ, Reynolds N, Ho JH, Adam S, Board R (2021) Diabetes mellitus in people with cancer. Endotext [Internet]"},{"issue":"7","key":"1697_CR32","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.3390\/ijms25073812","volume":"25","author":"K Kalinderi","year":"2024","unstructured":"Kalinderi K, Papaliagkas V, Fidani L (2024) GLP-1 receptor agonists: a new treatment in Parkinson\u2019s disease. Int J Mol Sci 25(7):3812. https:\/\/doi.org\/10.3390\/ijms25073812","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1697_CR33","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s00424-020-02441-x","volume":"472","author":"H Koepsell","year":"2020","unstructured":"Koepsell H (2020) Glucose transporters in brain in health and disease. Pflugers Arch 472(9):1299\u20131343. https:\/\/doi.org\/10.1007\/s00424-020-02441-x","journal-title":"Pflugers Arch"},{"issue":"4","key":"1697_CR34","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.3233\/JPD-212725","volume":"11","author":"K Komici","year":"2021","unstructured":"Komici K, Femminella GD, Bencivenga L, Rengo G, Pagano G (2021) Diabetes mellitus and parkinson\u2019s disease: a systematic review and meta-analyses. J Parkinsons Dis 11(4):1585\u20131596. https:\/\/doi.org\/10.3233\/JPD-212725","journal-title":"J Parkinsons Dis"},{"issue":"5","key":"1697_CR35","doi-asserted-by":"publisher","first-page":"4687","DOI":"10.3390\/ijms24054687","volume":"24","author":"T-T Kuo","year":"2023","unstructured":"Kuo T-T, Chen Y-H, Wang V, Huang EY-K, Ma K-H, Greig NH, Jung J, Choi H-I, Olson L, Hoffer BJ (2023) PT320, a sustained-release GLP-1 receptor agonist, ameliorates L-DOPA-induced dyskinesia in a mouse model of parkinson\u2019s disease. Int J Mol Sci 24(5):4687. https:\/\/doi.org\/10.3390\/ijms24054687","journal-title":"Int J Mol Sci"},{"key":"1697_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112335","author":"H Li","year":"2023","unstructured":"Li H, Guglielmetti C, Sei YJ, Zilberter M, Le Page LM, Shields L, Yang J, Nguyen K, Tiret B, Gao X (2023) Neurons require glucose uptake and glycolysis in vivo. Cell Rep. https:\/\/doi.org\/10.1016\/j.celrep.2023.112335","journal-title":"Cell Rep"},{"issue":"2","key":"1697_CR37","doi-asserted-by":"publisher","first-page":"e14411","DOI":"10.1111\/cns.14411","volume":"30","author":"H Li","year":"2024","unstructured":"Li H, Zeng F, Huang C, Pu Q, Thomas ER, Chen Y, Li X (2024) The potential role of glucose metabolism, lipid metabolism, and amino acid metabolism in the treatment of Parkinson\u2019s disease. CNS Neurosci Ther 30(2):e14411. https:\/\/doi.org\/10.1111\/cns.14411","journal-title":"CNS Neurosci Ther"},{"key":"1697_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2025.101719","author":"T Liu","year":"2025","unstructured":"Liu T, Li J, Wu H, Qiao J, Wei J (2025) Unraveling parkinson\u2019s disease: the mystery of mitochondria and the role of aging. Genes Dis. https:\/\/doi.org\/10.1016\/j.gendis.2025.101719. Advance online publication","journal-title":"Genes Dis"},{"key":"1697_CR39","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s12035-018-1099-4","volume":"56","author":"AJ L\u00f3pez-Gambero","year":"2019","unstructured":"L\u00f3pez-Gambero AJ, Mart\u00ednez F, Salazar K, Cifuentes M, Nualart F (2019) Brain glucose-sensing mechanism and energy homeostasis. Mol Neurobiol 56:769\u2013796. https:\/\/doi.org\/10.1007\/s12035-018-1099-4","journal-title":"Mol Neurobiol"},{"issue":"1","key":"1697_CR40","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S1474-4422(23)00378-2","volume":"23","author":"A McGarry","year":"2024","unstructured":"McGarry A, Rosanbalm S, Leinonen M, Olanow CW, To D, Bell A, Lee D, Chang J, Dubow J, Dhall R (2024) Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 23(1):37\u201345","journal-title":"Lancet Neurol"},{"issue":"13","key":"1697_CR41","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","volume":"390","author":"WG Meissner","year":"2024","unstructured":"Meissner WG, Remy P, Giordana C, Malt\u00eate D, Derkinderen P, Hou\u00e9to J-L, Anheim M, Benatru I, Boraud T, Brefel-Courbon C (2024) Trial of lixisenatide in early parkinson\u2019s disease. N Engl J Med 390(13):1176\u20131185. https:\/\/doi.org\/10.1056\/NEJMoa2312323","journal-title":"N Engl J Med"},{"issue":"1","key":"1697_CR42","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3233\/JPD-2011-11023","volume":"1","author":"GE Meredith","year":"2011","unstructured":"Meredith GE, Rademacher DJ (2011) MPTP mouse models of parkinson\u2019s disease: an update. J Parkinsons Dis 1(1):19\u201333. https:\/\/doi.org\/10.3233\/JPD-2011-11023","journal-title":"J Parkinsons Dis"},{"issue":"10","key":"1697_CR43","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.tins.2013.07.001","volume":"36","author":"P Mergenthaler","year":"2013","unstructured":"Mergenthaler P, Lindauer U, Dienel GA, Meisel A (2013) Sugar for the brain: the role of glucose in physiological and pathological brain function. Trends Neurosci 36(10):587\u2013597. https:\/\/doi.org\/10.1016\/j.tins.2013.07.001","journal-title":"Trends Neurosci"},{"issue":"1","key":"1697_CR44","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12964-023-01402-y","volume":"22","author":"Y Miao","year":"2024","unstructured":"Miao Y, Meng H (2024) The involvement of \u03b1-synucleinopathy in the disruption of microglial homeostasis contributes to the pathogenesis of parkinson\u2019s disease. Cell Communication Signal 22(1):31. https:\/\/doi.org\/10.1186\/s12964-023-01402-y","journal-title":"Cell Communication Signal"},{"key":"1697_CR45","doi-asserted-by":"publisher","first-page":"101234","DOI":"10.1016\/j.molmet.2021.101234","volume":"52","author":"JL Milstein","year":"2021","unstructured":"Milstein JL, Ferris HA (2021) The brain as an insulin-sensitive metabolic organ. Mol Metab 52:101234. https:\/\/doi.org\/10.1016\/j.molmet.2021.101234","journal-title":"Mol Metab"},{"key":"1697_CR46","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.neuro.2016.03.005","volume":"54","author":"C Morland","year":"2016","unstructured":"Morland C, Pettersen MN, Hassel B (2016) Hyperosmolar sodium chloride is toxic to cultured neurons and causes reduction of glucose metabolism and ATP levels, an increase in glutamate uptake, and a reduction in cytosolic calcium. Neurotoxicology 54:34\u201343","journal-title":"Neurotoxicology"},{"key":"1697_CR47","doi-asserted-by":"publisher","first-page":"CD012990","DOI":"10.1002\/14651858.CD012990.pub2","volume":"7","author":"CA Mulvaney","year":"2020","unstructured":"Mulvaney CA, Duarte GS, Handley J, Evans DJW, Menon S, Wyse R, Emsley HCA (2020) GLP-1 receptor agonists for Parkinson\u2019s disease. Cochrane Database Syst Rev 7:CD012990. https:\/\/doi.org\/10.1002\/14651858.CD012990.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"1697_CR48","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40495-019-00191-8","volume":"5","author":"A Nasrolahi","year":"2019","unstructured":"Nasrolahi A, Mahmoudi J, Noori-Zadeh A, Haghani K, Bakhtiyari S, Darabi S (2019) Shared pathological mechanisms between diabetes mellitus and neurodegenerative diseases. Curr Pharmacol Rep 5:219\u2013231. https:\/\/doi.org\/10.1007\/s40495-019-00191-8","journal-title":"Curr Pharmacol Rep"},{"key":"1697_CR49","doi-asserted-by":"publisher","first-page":"101979","DOI":"10.1016\/j.arr.2023.101979","volume":"89","author":"J Nowell","year":"2023","unstructured":"Nowell J, Blunt E, Gupta D, Edison P (2023) Antidiabetic agents as a novel treatment for Alzheimer\u2019s and Parkinson\u2019s disease. Ageing Res Rev 89:101979. https:\/\/doi.org\/10.1016\/j.arr.2023.101979","journal-title":"Ageing Res Rev"},{"key":"1697_CR50","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s10495-007-0756-2","volume":"12","author":"M Ott","year":"2007","unstructured":"Ott M, Gogvadze V, Orrenius S, Zhivotovsky B (2007) Mitochondria, oxidative stress and cell death. Apoptosis 12:913\u2013922. https:\/\/doi.org\/10.1007\/s10495-007-0756-2","journal-title":"Apoptosis"},{"issue":"2","key":"1697_CR51","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1007\/s12035-015-9672-6","volume":"54","author":"SG Patching","year":"2017","unstructured":"Patching SG (2017) Glucose transporters at the blood-brain barrier: function, regulation and gateways for drug delivery. Mol Neurobiol 54(2):1046\u20131077. https:\/\/doi.org\/10.1007\/s12035-015-9672-6","journal-title":"Mol Neurobiol"},{"key":"1697_CR52","doi-asserted-by":"publisher","first-page":"154869","DOI":"10.1016\/j.metabol.2021.154869","volume":"123","author":"W Peng","year":"2021","unstructured":"Peng W, Tan C, Mo L, Jiang J, Zhou W, Du J, Zhou X, Liu X, Chen L (2021) Glucose transporter 3 in neuronal glucose metabolism: health and diseases. Metabolism 123:154869. https:\/\/doi.org\/10.1016\/j.metabol.2021.154869","journal-title":"Metabolism"},{"key":"1697_CR53","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11011-020-00636-w","volume":"36","author":"T Pingale","year":"2021","unstructured":"Pingale T, Gupta GL (2021) Current and emerging therapeutic targets for Parkinson\u2019s disease. Metab Brain Dis 36:13\u201327. https:\/\/doi.org\/10.1007\/s11011-020-00636-w","journal-title":"Metab Brain Dis"},{"issue":"13","key":"1697_CR54","doi-asserted-by":"publisher","first-page":"10449","DOI":"10.3390\/ijms241310449","volume":"24","author":"M-S Popoviciu","year":"2023","unstructured":"Popoviciu M-S, P\u0103duraru L, Yahya G, Metwally K, Cavalu S (2023) Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials. Int J Mol Sci 24(13):10449. https:\/\/doi.org\/10.3390\/ijms241310449","journal-title":"Int J Mol Sci"},{"key":"1697_CR55","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/82_2010_83","volume":"345","author":"A Quaegebeur","year":"2010","unstructured":"Quaegebeur A, Carmeliet P (2010) Oxygen sensing: a common crossroad in cancer and neurodegeneration. Diverse Eff Hypoxia Tumor Progression 345:71\u2013103. https:\/\/doi.org\/10.1007\/82_2010_83","journal-title":"Diverse Eff Hypoxia Tumor Progression"},{"issue":"1","key":"1697_CR56","doi-asserted-by":"publisher","first-page":"24","DOI":"10.37349\/ent.2023.00036","volume":"3","author":"K Radad","year":"2023","unstructured":"Radad K, Moldzio R, Krewenka C, Kranner B, Rausch W-D (2023) Pathophysiology of non-motor signs in parkinsons disease: some recent updating with brief presentation. Explor Neuroprotective Therapy 3(1):24\u201346. https:\/\/doi.org\/10.37349\/ent.2023.00036","journal-title":"Explor Neuroprotective Therapy"},{"issue":"16","key":"1697_CR57","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.3390\/nu15163585","volume":"15","author":"VA Ruiz-Pozo","year":"2023","unstructured":"Ruiz-Pozo VA, Tamayo-Trujillo R, Cadena-Ullauri S, Frias-Toral E, Guevara-Ram\u00edrez P, Paz-Cruz E, Chapela S, Montalv\u00e1n M, Morales-L\u00f3pez T, Simancas-Racines D (2023) The molecular mechanisms of the relationship between insulin resistance and Parkinson\u2019s disease pathogenesis. Nutrients 15(16):3585. https:\/\/doi.org\/10.3390\/nu15163585","journal-title":"Nutrients"},{"issue":"10","key":"1697_CR58","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.parkreldis.2015.07.017","volume":"21","author":"K S\u00e4\u00e4ksj\u00e4rvi","year":"2015","unstructured":"S\u00e4\u00e4ksj\u00e4rvi K, Knekt P, M\u00e4nnist\u00f6 S, Lyytinen J, Heli\u00f6vaara M (2015) Prospective study on the components of metabolic syndrome and the incidence of Parkinson\u2019s disease. Parkinsonism Relat Disord 21(10):1148\u20131155. https:\/\/doi.org\/10.1016\/j.parkreldis.2015.07.017","journal-title":"Parkinsonism Relat Disord"},{"issue":"8","key":"1697_CR59","doi-asserted-by":"publisher","first-page":"4547","DOI":"10.1007\/s12035-023-03359-y","volume":"60","author":"SS Sabari","year":"2023","unstructured":"Sabari SS, Balasubramani K, Iyer M, Sureshbabu HW, Venkatesan D, Gopalakrishnan AV, Narayanaswamy A, Senthil Kumar N, Vellingiri B (2023) Type 2 diabetes (T2DM) and parkinson\u2019s disease (PD): a mechanistic approach. Mol Neurobiol 60(8):4547\u20134573. https:\/\/doi.org\/10.1007\/s12035-023-03359-y","journal-title":"Mol Neurobiol"},{"key":"1697_CR60","doi-asserted-by":"publisher","first-page":"117862","DOI":"10.1002\/mds.27128","volume":"183","author":"M Salvad\u00e8","year":"2025","unstructured":"Salvad\u00e8 M, DiLuca M, Gardoni F (2025) An update on drug repurposing in parkinson\u2019s disease: preclinical and clinical considerations. Biomed Pharmacother 183:117862. https:\/\/doi.org\/10.1002\/mds.27128","journal-title":"Biomed Pharmacother"},{"key":"1697_CR61","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jconrel.2016.05.044","volume":"235","author":"C Saraiva","year":"2016","unstructured":"Saraiva C, Pra\u00e7a C, Ferreira R, Santos T, Ferreira L, Bernardino L (2016) Nanoparticle-mediated brain drug delivery: overcoming blood\u2013brain barrier to treat neurodegenerative diseases. J Control Release 235:34\u201347. https:\/\/doi.org\/10.1016\/j.jconrel.2016.05.044","journal-title":"J Control Release"},{"issue":"1","key":"1697_CR62","doi-asserted-by":"publisher","first-page":"48","DOI":"10.2174\/1567202610666131124234506","volume":"11","author":"S Sarkar","year":"2014","unstructured":"Sarkar S, Raymick J, Mann D, Bowyer F, Hanig JP, Schmued JC, Paule LG, M., Chigurupati S (2014) Neurovascular changes in acute, sub-acute and chronic mouse models of parkinson\u2019s disease. Curr Neurovasc Res 11(1):48\u201361","journal-title":"Curr Neurovasc Res"},{"key":"1697_CR63","doi-asserted-by":"crossref","unstructured":"Sch\u00e4fer G, Penefsky H (2008) Bioenergetics: energy conservation and conversion, vol 45. Springer Science & Business Media","DOI":"10.1007\/978-3-540-78622-1"},{"issue":"10","key":"1697_CR64","doi-asserted-by":"publisher","first-page":"12629","DOI":"10.3390\/ijms131012629","volume":"13","author":"K Shah","year":"2012","unstructured":"Shah K, DeSilva S, Abbruscato T (2012) The role of glucose transporters in brain disease: diabetes and Alzheimer\u2019s disease. Int J Mol Sci 13(10):12629\u201312655. https:\/\/doi.org\/10.3390\/ijms131012629","journal-title":"Int J Mol Sci"},{"issue":"12","key":"1697_CR65","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.3390\/biomedicines12122841","volume":"12","author":"J Sian-Hulsmann","year":"2024","unstructured":"Sian-Hulsmann J, Riederer P, Michel TM (2024) Metabolic dysfunction in Parkinson\u2019s disease: unraveling the glucose\u2013lipid connection. Biomedicines 12(12):2841. https:\/\/doi.org\/10.3390\/biomedicines12122841","journal-title":"Biomedicines"},{"issue":"2","key":"1697_CR66","doi-asserted-by":"publisher","first-page":"a009399","DOI":"10.1101\/cshperspect.a009399","volume":"2","author":"L Stefanis","year":"2012","unstructured":"Stefanis L (2012) \u03b1-Synuclein in parkinson\u2019s disease. Cold Spring Harbor Perspect Med 2(2):a009399. https:\/\/doi.org\/10.1101\/cshperspect.a009399","journal-title":"Cold Spring Harbor Perspect Med"},{"issue":"9942","key":"1697_CR67","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/S0140-6736(14)60041-6","volume":"384","author":"AJ Stoessl","year":"2014","unstructured":"Stoessl AJ, Lehericy S, Strafella AP (2014) Imaging insights into basal ganglia function, Parkinson\u2019s disease, and dystonia. Lancet 384(9942):532\u2013544","journal-title":"Lancet"},{"issue":"10","key":"1697_CR68","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.3390\/life13102044","volume":"13","author":"RC Subtirelu","year":"2023","unstructured":"Subtirelu RC, Teichner EM, Su Y, Al-Daoud O, Patel M, Patil S, Writer M, Werner T, Revheim M-E, H\u00f8ilund-Carlsen PF (2023) Aging and cerebral glucose metabolism: 18F-FDG-PET\/CT reveals distinct global and regional metabolic changes in healthy patients. Life 13(10):2044. https:\/\/doi.org\/10.3390\/life13102044","journal-title":"Life"},{"issue":"15","key":"1697_CR69","doi-asserted-by":"publisher","first-page":"8142","DOI":"10.3390\/ijms22158142","volume":"22","author":"L Szablewski","year":"2021","unstructured":"Szablewski L (2021) Brain glucose transporters: role in pathogenesis and potential targets for the treatment of Alzheimer\u2019s disease. Int J Mol Sci 22(15):8142. https:\/\/doi.org\/10.3390\/ijms22158142","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1697_CR70","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/0304-3940(96)12357-0","volume":"204","author":"M Takahashi","year":"1996","unstructured":"Takahashi M, Yamada T, Tooyama I, Moroo I, Kimura H, Yamamoto T, Okada H (1996) Insulin receptor mRNA in the substantia nigra in parkinson\u2019s disease. Neurosci Lett 204(3):201\u2013204. https:\/\/doi.org\/10.1016\/0304-3940(96)12357-0","journal-title":"Neurosci Lett"},{"issue":"22","key":"1697_CR71","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.3390\/cells13221876","volume":"13","author":"A Tanvir","year":"2024","unstructured":"Tanvir A, Jo J, Park SM (2024) Targeting glucose metabolism: a novel therapeutic approach for parkinson\u2019s disease. Cells 13(22):1876. https:\/\/doi.org\/10.3390\/cells13221876","journal-title":"Cells"},{"key":"1697_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/diseases13030082","author":"R Tenchov","year":"2025","unstructured":"Tenchov R, Sasso JM, Zhou QA (2025) Evolving landscape of Parkinson\u2019s disease research: challenges and perspectives. ACS Omega. https:\/\/doi.org\/10.3390\/diseases13030082","journal-title":"ACS Omega"},{"key":"1697_CR73","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.nicl.2014.06.007","volume":"5","author":"LK Teune","year":"2014","unstructured":"Teune LK, Renken RJ, De Jong BM, Willemsen AT, Van Osch MJ, Roerdink JB, Dierckx RA, Leenders KL (2014) Parkinson\u2019s disease-related perfusion and glucose metabolic brain patterns identified with PCASL-MRI and FDG-PET imaging. Neuroimage Clin 5:240\u2013244. https:\/\/doi.org\/10.1016\/j.nicl.2014.06.007","journal-title":"Neuroimage Clin"},{"issue":"1","key":"1697_CR74","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nrn2294","volume":"9","author":"DR Tomlinson","year":"2008","unstructured":"Tomlinson DR, Gardiner NJ (2008) Glucose neurotoxicity. Nat Rev Neurosci 9(1):36\u201345","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"1697_CR75","doi-asserted-by":"publisher","first-page":"e14426","DOI":"10.1111\/cbdd.14426","volume":"103","author":"A Verma","year":"2024","unstructured":"Verma A, Chaudhary S, Solanki K, Goyal A, Yadav HN (2024) Exendin-4: a potential therapeutic strategy for Alzheimer\u2019s disease and Parkinson\u2019s disease. Chem Biol Drug Des 103(1):e14426. https:\/\/doi.org\/10.1111\/cbdd.14426","journal-title":"Chem Biol Drug Des"},{"issue":"4","key":"1697_CR76","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1080\/01635581.2017.1295090","volume":"69","author":"G Wang","year":"2017","unstructured":"Wang G, Wang J-J, Guan R, Du L, Gao J, Fu X-L (2017) Strategies to target glucose metabolism in tumor microenvironment on cancer by flavonoids. Nutr Cancer 69(4):534\u2013554. https:\/\/doi.org\/10.1080\/01635581.2017.1295090","journal-title":"Nutr Cancer"},{"key":"1697_CR77","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S471744","author":"Y Wang","year":"2024","unstructured":"Wang Y, Lv B, Fan K, Su C, Xu D, Pan J (2024) Metabolic disturbances in a mouse model of MPTP\/Probenecid-induced parkinson\u2019s disease: evaluation using liquid chromatography-mass spectrometry. Neuropsychiatr Dis Treat. https:\/\/doi.org\/10.2147\/NDT.S471744","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"5","key":"1697_CR78","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/14728222.2022.2079492","volume":"26","author":"X Yang","year":"2022","unstructured":"Yang X, Feng P, Ji R, Ren Y, Wei W, H\u00f6lscher C (2022) Therapeutic application of GLP-1 and GIP receptor agonists in parkinson\u2019s disease. Expert Opin Ther Targets 26(5):445\u2013460. https:\/\/doi.org\/10.1080\/14728222.2022.2079492","journal-title":"Expert Opin Ther Targets"},{"issue":"22","key":"1697_CR79","doi-asserted-by":"publisher","first-page":"16480","DOI":"10.3390\/ijms242216480","volume":"24","author":"CY Yonamine","year":"2023","unstructured":"Yonamine CY, Michalani MLE, Moreira RJ, Machado UF (2023) Glucose transport and utilization in the hippocampus: from neurophysiology to diabetes-related development of dementia. Int J Mol Sci 24(22):16480. https:\/\/doi.org\/10.3390\/ijms242216480","journal-title":"Int J Mol Sci"},{"key":"1697_CR80","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3389\/fnins.2020.00785","volume":"14","author":"S-J Yu","year":"2020","unstructured":"Yu S-J, Chen S, Yang Y-Y, Glotfelty EJ, Jung J, Kim HK, Choi H-I, Choi D-S, Hoffer BJ, Greig NH (2020) PT320, sustained-release exendin-4, mitigates L-DOPA-induced dyskinesia in a rat 6-hydroxydopamine model of parkinson\u2019s disease. Front Neurosci 14:785. https:\/\/doi.org\/10.3389\/fnins.2020.00785","journal-title":"Front Neurosci"},{"issue":"8","key":"1697_CR81","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.4103\/1673-5374.360242","volume":"18","author":"H-Y Yu","year":"2023","unstructured":"Yu H-Y, Sun T, Wang Z, Li H, Xu D, An J, Wen L-L, Li J-Y, Li W, Feng J (2023) Exendin-4 and linagliptin attenuate neuroinflammation in a mouse model of Parkinson\u2019s disease. Neural Regen Res 18(8):1818\u20131826. https:\/\/doi.org\/10.4103\/1673-5374.360242","journal-title":"Neural Regen Res"},{"issue":"18","key":"1697_CR82","doi-asserted-by":"publisher","first-page":"e3549","DOI":"10.1097\/MD.0000000000003549","volume":"95","author":"X Yue","year":"2016","unstructured":"Yue X, Li H, Yan H, Zhang P, Chang L, Li T (2016) Risk of Parkinson disease in diabetes mellitus: an updated meta-analysis of population-based cohort studies. Medicine (Baltimore) 95(18):e3549. https:\/\/doi.org\/10.1097\/MD.0000000000003549","journal-title":"Medicine (Baltimore)"},{"key":"1697_CR83","doi-asserted-by":"publisher","first-page":"1192602","DOI":"10.3389\/fendo.2023.1192602","volume":"14","author":"S Zhang","year":"2023","unstructured":"Zhang S, Zhang Y, Wen Z, Yang Y, Bu T, Bu X, Ni Q (2023a) Cognitive dysfunction in diabetes: abnormal glucose metabolic regulation in the brain. Front Endocrinol 14:1192602. https:\/\/doi.org\/10.3389\/fendo.2023.1192602","journal-title":"Front Endocrinol"},{"key":"1697_CR84","doi-asserted-by":"publisher","first-page":"1217451","DOI":"10.3389\/fnins.2023.1217451","volume":"17","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Qi Y, Gao Y, Chen W, Zhou T, Zang Y, Li J (2023b) Astrocyte metabolism and signaling pathways in the CNS. Front Neurosci 17:1217451. https:\/\/doi.org\/10.3389\/fnins.2023.1217451","journal-title":"Front Neurosci"}],"container-title":["Metabolic Brain Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-025-01697-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11011-025-01697-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-025-01697-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T10:58:53Z","timestamp":1761303533000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11011-025-01697-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":84,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["1697"],"URL":"https:\/\/doi.org\/10.1007\/s11011-025-01697-5","relation":{},"ISSN":["1573-7365"],"issn-type":[{"value":"1573-7365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"253"}}